These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 28532239)

  • 1. Status and trend analysis of prophylactic usage of recombinant factor VIII in Chinese pediatric patients with hemophilia A: ReCare - a retrospective, phase IV, non-interventional study.
    Li C; Zhang X; Zhao Y; Wu R; Hu Q; Xu V; Sun J; Yang R; Li X; Zhou R; Lian S; Gu J; Wu J; Hou Q
    Curr Med Res Opin; 2017 Sep; 33(9):1571-1578. PubMed ID: 28532239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term efficacy and safety of prophylaxis with recombinant factor VIII in Chinese pediatric patients with hemophilia A: a multi-center, retrospective, non-interventional, phase IV (ReCARE) study.
    Li C; Zhang X; Zhao Y; Wu R; Hu Q; Xu W; Sun J; Yang R; Li X; Zhou R; Lian S; Gu J; Wu J; Hou Q
    Curr Med Res Opin; 2017 Jul; 33(7):1223-1230. PubMed ID: 28326849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Efficacy of Recombinant FVIII Low-Dose Prophylaxis in Chinese Pediatric Patients With Severe Hemophilia A: A Retrospective Analysis From the ReCARE Study.
    Yao W; Xiao J; Cheng X; Feng G; Li C; Zhang X; Hu Q; Xu W; Sun J; Yang R; Li X; Zhou R; Lian S; Gu J; Wu J; Zhao Y; Wu R
    Clin Appl Thromb Hemost; 2017 Oct; 23(7):851-858. PubMed ID: 27920236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing Factor Use and Bleed Rates in U.S. Hemophilia A Patients Receiving Prophylaxis with 3 Different Long-Acting Recombinant Factor VIII Products.
    Simpson ML; Desai V; Maro GS; Yan S
    J Manag Care Spec Pharm; 2020 Apr; 26(4):504-512. PubMed ID: 32020842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of standard prophylaxis versus on-demand treatment with bayer's sucrose-formulated recombinant FVIII (rFVIII-FS) in Chinese children with severe hemophilia A.
    Zhao Y; Xiao J; Yang R; Wu R; Hu Y; Beckmann H; Wu J; Hou Q; Sun J
    Pediatr Hematol Oncol; 2017 Apr; 34(3):138-148. PubMed ID: 28727494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Retrospective Observational Study of Rurioctocog Alfa Pegol in Clinical Practice in the United States.
    Aledort L; Milligan S; Watt M; Booth J
    J Manag Care Spec Pharm; 2020 Apr; 26(4):492-503. PubMed ID: 32223610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting the outcomes of using longer-acting prophylactic factor VIII to treat people with severe hemophilia A: a hypothetical decision analysis.
    Miners AH; Krishnan S; Pasi KJ
    J Thromb Haemost; 2016 Nov; 14(11):2141-2147. PubMed ID: 27510890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness of full-length and B-domain deleted factor VIII for prophylaxis--a meta-analysis.
    Gruppo RA; Brown D; Wilkes MM; Navickis RJ
    Haemophilia; 2003 May; 9(3):251-60. PubMed ID: 12694514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective analysis of differences in annual factor VIII utilization among haemophilia A patients.
    Epstein J; Xiong Y; Woo P; Li-McLeod J; Spotts G
    Haemophilia; 2012 Mar; 18(2):187-92. PubMed ID: 21883704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART).
    Manco-Johnson MJ; Kempton CL; Reding MT; Lissitchkov T; Goranov S; Gercheva L; Rusen L; Ghinea M; Uscatescu V; Rescia V; Hong W
    J Thromb Haemost; 2013 Jun; 11(6):1119-27. PubMed ID: 23528101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indirect comparisons of efficacy and weekly factor consumption during continuous prophylaxis with recombinant factor VIII Fc fusion protein and conventional recombinant factor VIII products.
    Iorio A; Krishnan S; Myrén KJ; Lethagen S; McCormick N; Yermakov S; Karner P
    Haemophilia; 2017 May; 23(3):408-416. PubMed ID: 28233383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in Sweden.
    Henry N; Jovanović J; Schlueter M; Kritikou P; Wilson K; Myrén KJ
    J Med Econ; 2018 Apr; 21(4):318-325. PubMed ID: 29139314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SHP656, a polysialylated recombinant factor VIII (PSA-rFVIII): First-in-human study evaluating safety, tolerability and pharmacokinetics in patients with severe haemophilia A.
    Tiede A; Allen G; Bauer A; Chowdary P; Collins P; Goldstein B; Jiang HJ; Kӧck K; Takács I; Timofeeva M; Wolfsegger M; Srivastava S
    Haemophilia; 2020 Jan; 26(1):47-55. PubMed ID: 31778283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter pharmacosurveillance study for the evaluation of the efficacy and safety of recombinant factor VIII in the treatment of patients with hemophilia A. German Kogenate Study Group.
    Aygören-Pürsün E; Scharrer I
    Thromb Haemost; 1997 Nov; 78(5):1352-6. PubMed ID: 9408018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A. The Recombinate Previously Treated Patient Study Group.
    White GC; Courter S; Bray GL; Lee M; Gomperts ED
    Thromb Haemost; 1997 Apr; 77(4):660-7. PubMed ID: 9134639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients.
    Powell JS; Josephson NC; Quon D; Ragni MV; Cheng G; Li E; Jiang H; Li L; Dumont JA; Goyal J; Zhang X; Sommer J; McCue J; Barbetti M; Luk A; Pierce GF
    Blood; 2012 Mar; 119(13):3031-7. PubMed ID: 22223821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor VIII.
    Hermans C; Mahlangu J; Booth J; Schütz H; Santagostino E; Young G; Lee HY; Steinitz-Trost KN; Blanchette V; Berntorp E
    Haemophilia; 2018 May; 24(3):376-384. PubMed ID: 29732708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing prophylactic use and clinical outcomes in hemophilia A patients treated with rVIII-SingleChain and other common rFVIII products in Germany.
    Olivieri M; Sommerer P; Maro G; Yan S
    Eur J Haematol; 2020 Apr; 104(4):310-317. PubMed ID: 31883398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolonged bleeding-free period following prophylactic infusion of recombinant factor VIII reconstituted with pegylated liposomes.
    Spira J; Plyushch OP; Andreeva TA; Andreev Y
    Blood; 2006 Dec; 108(12):3668-73. PubMed ID: 16888098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics, coagulation factor consumption and clinical efficacy in patients being switched from full-length FVIII treatment to B-domain-deleted r-FVIII and back to full-length FVIII.
    Rea C; Dunkerley A; Sørensen B; Rangarajan S
    Haemophilia; 2009 Nov; 15(6):1237-42. PubMed ID: 19664015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.